Pixantrone maleate

• CAT Number: I008780
• CAS Number: 144675-97-8
• Molecular Formula: C₁₇H₁₉N₅O₂.C₈H₈O₈
• Molecular Weight: 557.52
• Purity: ≥95%
• Synonyms: BBR 2778
• Target: Topoisomerase
• Solubility: Soluble in DMSO and water
• Storage: -20°C
• Related CAS: 144510-96-3 (free base); 175989-38-5 (HCl)
• InChI: InChI=1S/C17H19N5O2.2C4H4O4/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24;2*5-3(6)1-2-4(7)8/h1-3,6,9,21-22H,4-5,7-8,18-19H2;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-
• InChIKey: SVAGFBGXEWPNJC-SPIKMXEPSA-N
• SMILES: C1=CC(=C2C(=C1NCCN)C(=O)C3=C(C2=O)C=NC=C3)NCCN.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O

Pixantrone maleate (CAT: I008780) is a chemotherapeutic agent used in the treatment of non-Hodgkin lymphoma. It belongs to the class of anthracene diones and works by intercalating DNA and inhibiting topoisomerase II, leading to DNA damage and cell death. Pixantrone has shown efficacy in treating relapsed or refractory aggressive B-cell lymphomas. Compared to other anthracycline drugs, it exhibits reduced cardiotoxicity while still maintaining anticancer activity. It is administered intravenously and may be used as part of combination chemotherapy regimens.

Reference

1: Volpetti S, Zaja F, Fanin R. Pixantrone for the treatment of adult patients
with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Onco Targets
Ther. 2014 May 29;7:865-72. doi: 10.2147/OTT.S34055. eCollection 2014. Review.
PubMed PMID: 24926199; PubMed Central PMCID: PMC4049882.

2: Papadatos-Pastos D, Pettengell R. Pixantrone: merging safety with efficacy.
Expert Rev Hematol. 2013 Feb;6(1):25-33. doi: 10.1586/ehm.12.61. Review. PubMed
PMID: 23373776.

3: Cabanillas F. Pixantrone: a new agent for relapsed aggressive lymphomas.
Lancet Oncol. 2012 Jul;13(7):654-6. doi: 10.1016/S1470-2045(12)70232-2. Epub 2012
May 30. PubMed PMID: 22652184.

4: Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H,
Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C,
Gorbatchevsky I, Singer JW. Pixantrone dimaleate versus other chemotherapeutic
agents as a single-agent salvage treatment in patients with relapsed or
refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label,
randomised trial. Lancet Oncol. 2012 Jul;13(7):696-706. doi:
10.1016/S1470-2045(12)70212-7. Epub 2012 May 30. Erratum in: Lancet Oncol. 2012
Jul;13(7):e285. PubMed PMID: 22652183.

5: Jamal-Hanjani M, Pettengell R. Pharmacokinetic evaluation of pixantrone for
the treatment of non-Hodgkin/’s lymphoma. Expert Opin Drug Metab Toxicol. 2011
Nov;7(11):1441-8. doi: 10.1517/17425255.2011.618834. Epub 2011 Sep 12. Review.
PubMed PMID: 21905966.

6: Srokowski TP, Liebmann JE, Modiano MR, Cohen GI, Pro B, Romaguera JE, Kuepfer
C, Singer JW, Fayad LE. Pixantrone dimaleate in combination with fludarabine,
dexamethasone, and rituximab in patients with relapsed or refractory indolent
non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort. Cancer. 2011
Nov 15;117(22):5067-73. doi: 10.1002/cncr.26121. Epub 2011 Jun 16. PubMed PMID:
21681734.

7: Adnan N, Buck DP, Evison BJ, Cutts SM, Phillips DR, Collins JG. DNA binding by
pixantrone. Org Biomol Chem. 2010 Dec 7;8(23):5359-66. doi: 10.1039/c0ob00295j.
Epub 2010 Sep 24. PubMed PMID: 20865205.

8: Mukherji D, Pettengell R. Pixantrone for the treatment of aggressive
non-Hodgkin lymphoma. Expert Opin Pharmacother. 2010 Aug;11(11):1915-23. doi:
10.1517/14656566.2010.494180. Review. PubMed PMID: 20569087.